These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32023984)

  • 1. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
    Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
    J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide.
    Motoyoshi Y; Kaminoda K; Saitoh O; Hamasaki K; Nakao K; Ishii N; Nagayama Y; Eguchi K
    Oncol Rep; 2006 Jul; 16(1):141-6. PubMed ID: 16786137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
    Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
    Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
    Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
    Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
    Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
    Hatiboglu MA; Kong LY; Wei J; Wang Y; McEnery KA; Fuller GN; Qiao W; Davies MA; Priebe W; Heimberger AB
    Int J Cancer; 2012 Jul; 131(1):8-17. PubMed ID: 21792892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
    Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
    Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
    Liu JY; Wu Y; Zhang XS; Yang JL; Li HL; Mao YQ; Wang Y; Cheng X; Li YQ; Xia JC; Masucci M; Zeng YX
    Cancer Immunol Immunother; 2007 Oct; 56(10):1597-604. PubMed ID: 17440723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.